Click on image to view larger version.
Figure 2. (a) 1 mCi diagnostic 131I-metaiodobenzylguanidine (MIBG) whole body scan 48 h post-injection demonstrated a well defined focal area of increased tracer uptake in midthoracic region (more evident in posterior view) and at an area inferomedial to the right lobe of liver. (b) Pre-therapy repeat 131I-MIBG posterior chest scan showing focal tracer uptake only at the region of T4–T6 vertebral lesions. Rest of the whole body survey did not reveal any abnormal tracer uptake.
